Literature DB >> 28277374

Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer.

Min S Kwak1, Jae M Cha1, Young H Cho1, Sang H Kim2, Jin Y Yoon1, Jung W Jeon1, Hyun P Shin1, Kwang R Joo1, Joung I Lee1.   

Abstract

GOALS: This study sought to clarify sex differences in KRAS mutations and clinical predictors of KRAS 13 codon mutations.
BACKGROUND: Sex differences in KRAS mutations and predictors for KRAS codon 13 mutations in colorectal cancer (CRC) are unclear. STUDY: Between October 2007 and May 2016, 328 patients underwent surgery for CRCs that were analyzed for KRAS mutations at a referral university hospital. Sex differences in the rates and distributions of KRAS mutations, and factors predictive of overall KRAS and KRAS codon 13 mutations were analyzed.
RESULTS: KRAS mutations were significantly more common in women than men patients (46.0% vs. 34.4%, P<0.033). However, no sex differences were detected for KRAS mutations by codon subtypes (P=0.592). The Gly13Asp (GGC>GAC) point mutation was identified only within codon 13 in both sexes. For right-sided CRC, KRAS mutations were twice as frequent in men as in women (univariate analysis; P=0.016, multivariate analysis; P=0.019). High-plasma cholesterol level was an independent predictive factor of KRAS codon 13 mutations by univariate (odds ratio, 1.013; 95% confidence interval, 1.003-1.023) and multivariate analysis (odds ratio, 1.011; 95% confidence interval, 1.001-1.021).
CONCLUSIONS: Sex differences may affect the presentation of KRAS mutations, as they were more frequently detected in women and in right-sided CRC in men. KRAS codon 13 mutations were significantly associated with high-plasma cholesterol. Further studies are needed on the clinical implications of this finding.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28277374     DOI: 10.1097/MCG.0000000000000809

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location.

Authors:  M Tabuso; M Christian; P K Kimani; K Gopalakrishnan; R P Arasaradnam
Journal:  Pathol Oncol Res       Date:  2020-06-27       Impact factor: 3.201

Review 2.  KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.

Authors:  Vlad-Adrian Afrăsânie; Mihai Vasile Marinca; Teodora Alexa-Stratulat; Bogdan Gafton; Marius Păduraru; Anca Maria Adavidoaiei; Lucian Miron; Cristina Rusu
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

3.  4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone provokes progression from chronic pancreatitis to pancreatic intraepithelial neoplasia.

Authors:  Xin Chen; Liang Sheng; Jiguang Ma; Dan Qi; Xuqi Li; Zheng Wang; Zheng Wu; Lucas Wong; Jason H Huang; Erxi Wu; Qingyong Ma; Dong Zhang
Journal:  iScience       Date:  2021-12-18

Review 4.  Bacterial Involvement in Progression and Metastasis of Colorectal Neoplasia.

Authors:  Kevin D Seely; Amanda D Morgan; Lauren D Hagenstein; Garrett M Florey; James M Small
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

5.  KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania.

Authors:  Costel Stelian Brinzan; Mariana Aschie; Georgeta Camelia Cozaru; Mariana Deacu; Eugen Dumitru; Ionut Burlacu; Anca Mitroi
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.